

DUSA PHARMACEUTICALS INC

Form 8-K

May 04, 2007

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 4, 2007

DUSA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

New Jersey
*(State or other
jurisdiction of
incorporation)*

0-19777
*(Commission File
Number)*

22-3103129
*(IRS Employer
Identification
Number)*

25 Upton Drive
Wilmington, Massachusetts 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition.

Item 9.01 Financial Statement and Exhibits.

SIGNATURES

EXHIBIT INDEX

EX-99: PRESS RELEASE

Table of Contents

Item 2.02 Results of Operations and Financial Condition.

On May 4, 2007, DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) issued a press release, attached to and made part of this report, announcing financial results for the first quarter ended March 31, 2007.

Item 9.01 Financial Statement and Exhibits.

Item No.	Description
99	Press Release, dated May 4, 2007

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DUSA PHARMACEUTICALS, INC.

Dated: May 4, 2007

By: /s/ D. Geoffrey Shulman

D. Geoffrey Shulman, MD, FRCPC
Director, Chairman of the Board and
Chief Executive Officer

Table of Contents

EXHIBIT INDEX

Item No.	Description
99	Press Release, dated May 4, 2007